Acute ischemic stroke caused by posterior circulation large vessel occlusions represents one of the most critical neurovascular emergencies. Although endovascular interventions have transformed stroke care, clinicians frequently face clinical dilemmas when managing patients with low National Institutes of Health Stroke Scale (NIHSS) scores. Specifically, the optimal application of bridging therapy in BAO—combining intravenous thrombolysis (IVT) with immediate mechanical thrombectomy (MT)—remains intensely debated for mild presentations. Patients presenting with an NIHSS score under 10 may appear clinically stable initially. However, acute basilar occlusion carries an unpredictable natural course that often leads to rapid deterioration, severe disability, or catastrophic brainstem infarction.

Understanding the Clinical Conundrum in Mild Basilar Stroke

Posterior circulation strokes account for approximately one-fifth of all ischemic strokes, with basilar artery occlusion representing the most devastating subtype. Despite lower baseline NIHSS scores, mild clinical deficits can conceal extensive underlying hemodynamic compromise. The posterior circulation anatomy often produces deceptive clinical pictures where subtle cranial neuropathies, mild ataxia, or isolated vertigo initially mask a life-threatening arterial blockage.

Consequently, clinicians must decide rapidly whether to administer intravenous thrombolysis before advancing to catheter angiography or proceed straight to direct mechanical thrombectomy. While intravenous alteplase or tenecteplase can promote early clot dissolution, concerns exist regarding potential delays to groin puncture, distal clot fragmentation, and intracranial hemorrhage. Conversely, relying solely on mechanical thrombectomy might overlook microvascular thrombosis in delicate perforating pontine branches.

Therefore, determining the comparative safety and clinical efficacy of bridging therapy versus direct endovascular intervention is vital. Observational registries and retrospective analyses offer invaluable insights into this dilemma, especially because conducting randomized trials in low-NIHSS basilar occlusions poses ethical and logistical hurdles. Clinicians must weigh the immediate benefits of systemic recanalization against procedural delays and procedural complication rates.

Evaluating Bridging Therapy in BAO Versus Direct Thrombectomy

Recent clinical studies have focused specifically on comparing bridging therapy against direct mechanical thrombectomy alone in mild basilar artery occlusion cohorts. In patients presenting within the standard thrombolytic therapeutic window and presenting with mild neurological deficits, bridging therapy demonstrates notable advantages in functional independence. By administering intravenous thrombolytic agents immediately upon diagnostic confirmation, neurointerventionalists can initiate biochemical clot lysis while the endovascular suite prepares for intervention.

Moreover, real-world registry data highlight that bridging therapy does not significantly prolong the time from hospital door to arterial puncture when integrated stroke pathways operate efficiently. Instead, pre-treatment thrombolysis frequently softens the thrombus burden, facilitating subsequent aspiration or stent-retriever engagement. Consequently, proceduralists often observe higher rates of first-pass recanalization and shorter overall procedure times in patients who receive prior intravenous thrombolysis.

Nevertheless, direct mechanical thrombectomy retains clinical value for specific patient populations. Individuals with absolute contraindications to systemic thrombolysis, such as recent major surgery, active bleeding diathesis, or therapeutic anticoagulation, rely entirely on primary mechanical intervention. Thus, comparative effectiveness studies reassure clinicians that while bridging therapy offers distinct benefits, direct thrombectomy remains a potent alternative when thrombolysis is clinically contraindicated.

Recanalization Efficacy and Microvascular Reperfusion Outcomes

Achieving complete and sustainable arterial recanalization represents the primary determinant of long-term functional recovery in posterior circulation stroke. In basilar artery occlusion, achieving an expanded Thrombolysis in Cerebral Infarction (eTICI) score of 2b or 3 is paramount for preserving critical brainstem nuclei and ascending reticular activating pathways. Bridging therapy consistently correlates with improved rates of successful angiographic reperfusion across multicenter observational cohorts.

Furthermore, systemic thrombolytic agents penetrate distal capillary beds that mechanical thrombectomy devices cannot physically reach. Basilar artery trunk recanalization alone may leave smaller pontine and cerebellar branches occluded by microemboli. Therefore, intravenous thrombolysis acts synergistically with mechanical retrieval to clear distal emboli, enhancing downstream microvascular perfusion throughout the posterior fossa.

In addition, intravenous fibrinolytics help mitigate the risk of early reocclusion following successful thrombectomy. Endothelial injury induced by thrombectomy passes can stimulate local platelet aggregation and secondary thrombosis. The residual systemic fibrinolytic activity from bridging therapy provides a protective antithrombotic milieu during the immediate post-reperfusion window. Consequently, patients receiving combination therapy often demonstrate superior 90-day modified Rankin Scale scores compared to those undergoing direct thrombectomy alone.

Safety Profiles and Hemorrhagic Transformation Risks

Safety considerations represent a major determinant in acute stroke decision-making, particularly concerning the risk of symptomatic intracranial hemorrhage (sICH). A frequent clinical hesitation with bridging therapy in mild stroke is the perceived danger of turning a mild deficit into a disabling or fatal hemorrhage. However, accumulating observational evidence demonstrates that intravenous thrombolysis does not significantly increase sICH rates when administered within established guidelines.

Specifically, patients with basilar artery occlusion presenting with low baseline NIHSS scores typically harbor smaller ischemic core volumes on initial neuroimaging. Because parenchymal hemorrhage correlates strongly with the extent of baseline infarction, these mild-deficit patients inherently possess a lower baseline risk of hemorrhagic transformation. Thus, the addition of systemic thrombolytics remains remarkably safe in this carefully selected subpopulation.

Furthermore, procedural safety metrics, such as arterial dissection, vessel perforation, and access-site complications, remain comparable between bridging therapy and direct thrombectomy groups. As long as strict blood pressure control is maintained during and after the intervention, bridging therapy exhibits an excellent safety profile. Overall, available evidence indicates that the therapeutic advantages of bridging therapy outweigh the theoretical hazards of hemorrhagic transformation in mild basilar artery occlusion.

Clinical Decision-Making and Protocols for Acute Care

Translating these findings into clinical practice requires standardized institutional protocols and interdisciplinary collaboration among emergency physicians, neurologists, and neurointerventionalists. In acute care settings, patients presenting with subtle posterior circulation symptoms require rapid diagnostic imaging, preferably utilizing non-contrast CT combined with CT angiography from aortic arch to vertex. If basilar artery occlusion is identified, clinical teams must initiate treatment pathways immediately regardless of low baseline NIHSS scores.

Additionally, stroke centers must adopt a drip-and-ship or parallel workflow model where intravenous thrombolysis begins immediately in the emergency department without delaying transport to the catheterization laboratory. Clinicians should not pause thrombolytic infusions to await clinical improvement, as transient stability often precedes catastrophic neurological worsening. Rapid progression to angiography ensures definitive mechanical removal if chemical lysis proves insufficient.

Moreover, post-procedural management requires rigorous intensive care unit monitoring. Clinicians must maintain tight blood pressure targets, monitor neurological status frequently, and obtain follow-up neuroimaging at 24 hours. Individualized decision-making should account for onset time, vascular anatomy, collateral circulation status, and patient comorbidities. Ultimately, an aggressive, protocolized bridging approach provides patients with mild basilar occlusions the greatest opportunity for long-term neurological recovery.

Frequently Asked Questions

What is bridging therapy in acute ischemic stroke?

Bridging therapy combines initial intravenous thrombolysis with immediate mechanical thrombectomy for acute ischemic stroke due to large vessel occlusion. This synergistic approach aims to achieve early chemical recanalization, soften the thrombus, and clear microvascular emboli while the endovascular catheterization team prepares for definitive mechanical clot retrieval in the angiography suite.

Why is basilar artery occlusion dangerous even with mild initial symptoms?

Basilar artery occlusion often presents deceptively with mild symptoms like dizziness, ataxia, or dysarthria. However, it carries high risks of rapid progression, brainstem ischemia, and fatal locked-in syndrome. Because collateral circulation can suddenly fail, early aggressive intervention is crucial before catastrophic neurological deterioration occurs in these patients.

Does bridging therapy increase the risk of brain hemorrhage in mild stroke?

Current clinical evidence indicates that bridging therapy does not significantly increase symptomatic intracranial hemorrhage in mild basilar occlusion compared to thrombectomy alone. Because patients with low NIHSS scores typically have smaller baseline ischemic core volumes, the risk of severe hemorrhagic transformation remains low when protocolized guidelines are followed.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

Bellavia S et al. Bridging therapy versus mechanical thrombectomy alone in patients with basilar artery occlusion and mild symptoms: a retrospective observational study. J Neurol. 2026 Jun 17. doi: 10.1007/s00415-026-13883-1. PMID: 42307788.

Cai L, Wang L, Campbell BCV, et al. Endovascular thrombectomy with versus without intravenous thrombolysis in patients with acute basilar artery occlusion: a systematic review and meta-analysis. Stroke Vasc Neurol. 2024;9(4):370-379.

Langezaal LCM, van der Hoeven EJRJ, Mont'Alverne FJA, et al. Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion. N Engl J Med. 2021;384(23):2193-2204.